Bronchiolitis and Synagis. CONTINUITY CLINIC Pretest Which of the following children should receive RSV prophylaxis during RSV season? Which of the following.

Slides:



Advertisements
Similar presentations
The Cost Effectiveness of RSV Prophylaxis: Using Decision Analysis to Build a Better Guideline Melony E. S. Sorbero, PhD, MS, MPH.
Advertisements

Immunization and RSV/Palivizumab Clinic Update Advances in preventative care for our pediatric population.
The Wheezing Child: assessment, treatment and referral
Case Study MICR 420 Emerging and Re-Emerging Infectious Diseases S2010 Case 10 Jessica Cisneros Susana Hernandez.
Plate 85 Viral Diseases of the Respiratory System.
NH Department of Health and Human Services Division of Public Health Services Influenza Seasonal and H1N1 Patricia Ingraham, MPH Communicable Disease Control.
Pertussis Disease Pertussis (‘whooping cough’) is a bacterial infection affecting the respiratory system, caused by the organism Bordetella pertussis.
Adriana Weinberg, MD University of Colorado Denver.
Influenza and Influenza Vaccine
RSV update Chuck Hui MD FRCPC Pediatric Infectious Diseases Medical Director, RSV Prophylaxis clinic CHEO MOHLTC Ontario RSV Prophylaxis program.
Influenza Annual Training Health, healing and hope.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
INFLUENZA (FLU) Management Presentation
Influenza Outbreaks and Cruise Ships Laura Martin 25 April 2002.
Perinatal Varicella By Rafat Mosalli MD FAAP FRCPC.
Department of Molecular Virology and Microbiology Swine ‘09 The 2009 H1N1 Influenza Pandemic.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.
Influenza Vaccination
Adult Immunization 2010 Influenza Segment This material is in the public domain This information is valid as of May 25, 2010.
Adult Immunization 2010 Herpes Zoster (Shingles) Segment This material is in the public domain This information is valid as of May 25, 2010.
EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global epidemics Influenza viruses.
EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global pandemics Influenza viruses.
Varicella Zoster Virus Herpesvirus (DNA) Primary infection results in varicella (chickenpox) Recurrent infection results in herpes zoster (shingles) Short.
Chickenpox in Children, Adults and Pregnancy: What to do?
Respiratory Syncytial Virus Sonia Leng Heather Leonard
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases Centers.
Asthma & Bronchiolitis in the Hospitalized Pediatric Patient October 2008 Brian W. Temple, MD Childhood Health Associates of Salem October 2008 Brian W.
RSV Bronchiolitis Mark A. Brown, M.D. Professor of Clinical Pediatrics Pediatric Pulmonary Section University of Arizona.
EMPLOYEE INFLUENZA VACCINATON. Influenza Vaccination (Your institution) is committed to keep both its employees and patients safe (Your institution) recognizes.
An International Case Study of Lung Transplantation
Respiratory Syncytial Virus Prophylaxis The criteria
Palivizumab: a centralised clinic Laura Marshall RCN Conference 13 th March 2008.
General Recommendations on Immunization Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Background CDC licensed VZV vaccine in 1995 The virus is known to enter through the respiratory tract and conjunctiva, where it then enters the bloodstream.
Insert Program or Hospital Logo Introduction The Respiratory Syncytial virus (RSV) was discovered in 1956 and has been since recognized as one of the most.
RSV Breanna Fretwell. History of RSV  DISCOVERED IN 1956  ONE OF THE MOST COMMON CAUSES OF CHILDHOOD ILLNESS  A MEMBER OF THE FAMILY PARAMYXOVIRIDAE.
-Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. -Cystic Fibrosis affects over 8,500 people in the UK. -Over.
PEDIATRIC ASTHMA Anna M. Suray, M.D Respiratory Update Weirton Medical Center March 17, 2008.
Immunoprophylaxis for Prevention of Severe RSV Bronchiolitis Ma. Teresa C. Ambat, MD Neonatology-TTUHSC11/21/2008.
PIDPIC SOT Working Group Pediatric Infectious Diseases Program for Immunocompromised Hosts.
Influenza of 1918 Danielle Albin Dane van Loon Matthew Litch.
Bacterial Pneumonia.
Age appears to be a significant effect modifier of the impact of palivizumab on RSV hospitalization risk. Given the rapid decrease of RSV risk with increasing.
RSV RT 265. Respiratory Syncytial Virus Manifests primarily as: Bronchiolitis Bronchiolitis Viral pneumonia Viral pneumonia Leading cause of lower respiratory.
June 2010 California Pertussis Update. Pertussis Background Pertussis is the most poorly controlled vaccine- preventable disease  Incidence increasing.
Croup and Bronchiolitis Karen D. Sawitz, MD St. Barnabas Hospital Department of Pediatrics.
July 29, Most common pathogen causing lower airway disease in infants and toddlers 90,000 hospitalizations/year $700 million/year for children.
Sendai virus: Illuminating parainfluenza virus dynamics in living animals Charles J. Russell, PhD postdoc: Crystal Burke, PhD Funding: NIAID R01AI
Visibility of Vaccination and How Do We Improve?
It’s Just Not the Flu Anymore Rick Hong, MD Associate Chairman CCHS EMC Medical Director, PHPS.
Samar Musmar,MD,FAAFP Vice Dean for Clinical Affairs An-Najah National University Faculty of Medicine Head, Medicine and Society Dep. Flu Vaccination in.
paramyxo.ppt Paramyxoviruses paramyxo.ppt.
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
RSV: RESPIRATORY SYNCYTIAL VIRUS Barbara Woodall.
Bronchiolitis Abdullah M. Al-Olayan MBBS, SBP, ABP. Assistant Professor of Pediatrics. Pediatric Pulmonologist.
Note to presenter: The National Immunization Program can provide a videotape with animated sequences illustrating the biology of active and passive immunity.
بسم الله الرحمن الرحيم. BronchiolitisBronchiolitis By Hana ’ a M.N. Tashkandi.
Dr. Athal Humo transient Passive immunity is achieved by administration of preformed antibodies to induce transient protection against an infectious.
Quick Insights on Some Viral Issues Dr. Haya Al-Tawalah Clinical Virologist.
To Dear Staff and Students The prevention of respiratory tract disease----- influenza The prevention of respiratory tract disease----- influenza.
I Introduction to influenza Department of Health 2016 Vaccination Campaign Training workshop Presentation developed by the National Institute for Communicable.
Respiratory Syncytial Virus (RSV) Ekaterina Kinnear & Ryan Russell, Imperial College London Importance RSV is a major cause of disease in childhood and.
Respiratory Viruses Respiratory diseases occur most frequently in colder weather, especially in raining season, and in cases of overcrowding. Causes of.
Influenza Vaccines MedCh 401 Lecture 5 19May06 KL Vadheim Lecture 4.
Paula Chilvers GPST2 November 2017
RSV Bronchiolitis.
A Case-based Approach to RSV Disease
RUBELLA Dr.T.V.Rao MD.
Presentation transcript:

Bronchiolitis and Synagis

CONTINUITY CLINIC Pretest Which of the following children should receive RSV prophylaxis during RSV season? Which of the following children should receive RSV prophylaxis during RSV season? A. 5 month former 34 weeker who attends day care and has a 5 yo brother B. 11 month former 27 weeker C. 7 month former 31 weeker D. 18 month patient with cystic fibrosis on home 02 E. 14 month Tetrology of Fallot patient F. 22 month former 32 weeker with BPD who required diuretics and steroids in October

CONTINUITY CLINIC Background Respiratory syncytial virus (RSV) is the primary cause of lower respiratory tract illness in young children. Respiratory syncytial virus (RSV) is the primary cause of lower respiratory tract illness in young children. Generally resolves uneventfully in otherwise healthy children. Generally resolves uneventfully in otherwise healthy children. High risk populations may develop severe and sometimes fatal lower respiratory tract infections. High risk populations may develop severe and sometimes fatal lower respiratory tract infections. :):)

CONTINUITY CLINIC Background RSV infection annually contributes up to 126,300 pediatric hospitalizations in the U.S. RSV infection annually contributes up to 126,300 pediatric hospitalizations in the U.S. Estimated annual hospitalization costs for RSV pneumonia in children <=4 years: $300 - $400 million (1998 $), now much greater. Estimated annual hospitalization costs for RSV pneumonia in children <=4 years: $300 - $400 million (1998 $), now much greater. Annual mortality due to RSV in infants and children is estimated to range from 200 to over 2,700. Annual mortality due to RSV in infants and children is estimated to range from 200 to over 2,700.

CONTINUITY CLINIC Microbiology Basics RSV is single-stranded RNA virus of Paramyxoviridae family RSV is single-stranded RNA virus of Paramyxoviridae family Two subtypes, A and B Two subtypes, A and B A subtypes cause more disease A subtypes cause more disease Within subtypes are several genotypes Within subtypes are several genotypes Strains have shifts each year, accounting for re- infections Strains have shifts each year, accounting for re- infections

CONTINUITY CLINIC Prematurity Prematurity increases risk of severe RSV infection. Prematurity increases risk of severe RSV infection. RSV Hospitalization Rate by Gestational Age at Birth

CONTINUITY CLINIC Epidemiology Worldwide RSV epidemics occur yearly Worldwide RSV epidemics occur yearly United States: November – April United States: November – April Peak: January – March (most areas) Peak: January – March (most areas) Peak: 2 – 3 months earlier (Southeast) Peak: 2 – 3 months earlier (Southeast) 80% RSV admissions occur within 4 months of discharge from NICU. 80% RSV admissions occur within 4 months of discharge from NICU. Respiratory Illness Hospitalization Rate by Month of Discharge from NICU in Infants <= 32 Weeks GA

CONTINUITY CLINIC Transmission Inoculation of nasal or ocular membranes after contact with virus containing secretions or fomites Inoculation of nasal or ocular membranes after contact with virus containing secretions or fomites Virus can survive for several hours on hands and fomites (WASH HANDS!!!) Virus can survive for several hours on hands and fomites (WASH HANDS!!!) Direct contact most common, large aerosol drops also implicated Direct contact most common, large aerosol drops also implicated Incubation is 2-8 days Incubation is 2-8 days Patients usually shed 3-8 days but can shed up to 4 weeks in young infants Patients usually shed 3-8 days but can shed up to 4 weeks in young infants

CONTINUITY CLINIC Immunity Almost everyone has been infected with RSV by age 3 Almost everyone has been infected with RSV by age 3 Does not convey total protection against reinfection Does not convey total protection against reinfection Can be infected more than once in same RSV season but usually 2d infection milder Can be infected more than once in same RSV season but usually 2d infection milder Transplacental Ab does not protect completely against infection but high Ab’s imply milder disease and usually is only in upper respiratory tract Transplacental Ab does not protect completely against infection but high Ab’s imply milder disease and usually is only in upper respiratory tract

CONTINUITY CLINIC Pathologic findings Necrosis of epithelial cells Necrosis of epithelial cells Proliferation of bronchiolar epithelium Proliferation of bronchiolar epithelium Infiltrates of monocytes and T cells around arterioles Infiltrates of monocytes and T cells around arterioles Neutrophils between vasculature and small airways Neutrophils between vasculature and small airways Leads to airway obstruction, air trapping, increased airway resistance Leads to airway obstruction, air trapping, increased airway resistance Increased incidence of wheezing as children grow older Increased incidence of wheezing as children grow older

CONTINUITY CLINIC Hospital therapy for RSV Care is mainly supportive (fluids, respiratory support) Care is mainly supportive (fluids, respiratory support) Trial (one dose) of beta-agonist if bronchospasm. D/C if not improvement Trial (one dose) of beta-agonist if bronchospasm. D/C if not improvement Steroids not recommended Steroids not recommended Ribavirin not recommended unless severe LRT infection Ribavirin not recommended unless severe LRT infection Neither RSVIG nor Synagis is effective in treatment of hospitalized children Neither RSVIG nor Synagis is effective in treatment of hospitalized children

CONTINUITY CLINIC RSVIG Was developed as hyperimmune globulin from donors with high titers of RSV antibody Was developed as hyperimmune globulin from donors with high titers of RSV antibody In trials reduced hospitalizations in high risk infants by 41-63% In trials reduced hospitalizations in high risk infants by 41-63% Increased morbidity and mortality in CHD patients Increased morbidity and mortality in CHD patients Interfered with immune response to live vaccines (MMR and varicella) Interfered with immune response to live vaccines (MMR and varicella) No longer used frequently No longer used frequently

CONTINUITY CLINIC Palivizumab (Synagis) Is monoclonal antibody (not blood product) against RSV F glycoprotein Is monoclonal antibody (not blood product) against RSV F glycoprotein Easier to administer than RSVIG Easier to administer than RSVIG Does not interfere with response to live vaccines Does not interfere with response to live vaccines A newer but similar product is MEDI-524 or Numax A newer but similar product is MEDI-524 or Numax More potent in animal trials More potent in animal trials Currently undergoing clinical evaluation Currently undergoing clinical evaluation

CONTINUITY CLINIC Synagis Synagis is available in 50 and 100 mg vials Synagis is available in 50 and 100 mg vials The cost is $725 per 50 mg and $1370 per 100 mg vial The cost is $725 per 50 mg and $1370 per 100 mg vial Synagis has a shelf life of 6 hours making drug wastage nearly inevitable Synagis has a shelf life of 6 hours making drug wastage nearly inevitable

CONTINUITY CLINIC Dosing of Synagis 15 mg/kg IM once per month for 5 doses 15 mg/kg IM once per month for 5 doses Begin before RSV season begins, October or November Begin before RSV season begins, October or November Once dosing begins, continue even if patient is past age of indication Once dosing begins, continue even if patient is past age of indication Continue even if breakthrough Continue even if breakthrough infection infection

CONTINUITY CLINIC Efficacy IMpact-RSV trial in BPD pts and preemies IMpact-RSV trial in BPD pts and preemies 55% reduction in RSV-associated hospitalizations vs placebo 55% reduction in RSV-associated hospitalizations vs placebo Trial in CHD pts Trial in CHD pts 45% fewer hospitalizations 45% fewer hospitalizations 73% fewer hospital days needing O2 73% fewer hospital days needing O2 56% fewer total hospital days 56% fewer total hospital days Trial in 421 preemies without CLD who received Synagis or placebo Trial in 421 preemies without CLD who received Synagis or placebo 50% fewer infants in Synagis group had recurrent wheezing 50% fewer infants in Synagis group had recurrent wheezing Shows that prevention of RSV LRTI may reduce risk of recurrent wheezing in preemies without CLD Shows that prevention of RSV LRTI may reduce risk of recurrent wheezing in preemies without CLD

CONTINUITY CLINIC Risk factors for severe disease Less than 6 months Less than 6 months Born during first half of RSV season Born during first half of RSV season Attending daycare Attending daycare Underlying lung disease Underlying lung disease Born before 35 weeks Born before 35 weeks Congenital heart disease Congenital heart disease Immunocompromised patients Immunocompromised patients SCIDS, leukemia, BM transplant SCIDS, leukemia, BM transplant Significant asthma (any age) Significant asthma (any age) Living at altitudes greater than 8000 feet Living at altitudes greater than 8000 feet Institutionalized elderly Institutionalized elderly

CONTINUITY CLINIC Adverse Reactions Extremely safe, no serious adverse events in two consecutive seasons seen Extremely safe, no serious adverse events in two consecutive seasons seen Severe hypersensitivity (less than 1 per 100,000) Severe hypersensitivity (less than 1 per 100,000) About 1 per 100 children will have anti-Synagis antibodies and antibody response declines with continued dosing About 1 per 100 children will have anti-Synagis antibodies and antibody response declines with continued dosing No resistance to Synagis by RSV seen No resistance to Synagis by RSV seen Doesn’t interfere with immunizations Doesn’t interfere with immunizations

CONTINUITY CLINIC Specific Recommendations BPD- younger than 2 yo needing medical therapy for lungs who required medical therapy within 6 mos of RSV season BPD- younger than 2 yo needing medical therapy for lungs who required medical therapy within 6 mos of RSV season CHD – under 2 who have hemodynamically significant CHD CHD – under 2 who have hemodynamically significant CHD Prematurity Prematurity ≤ 28 weeks, younger than 1 yr at start of season ≤ 28 weeks, younger than 1 yr at start of season wks, younger than 6 mos wks, younger than 6 mos consider for infants <6 mos if 2 risk factors (day care attendance, congenital abnormalities, NMD, school-aged sibs) consider for infants <6 mos if 2 risk factors (day care attendance, congenital abnormalities, NMD, school-aged sibs) Immunocompromised – no controlled studies but seems apparent that those with SCIDS or HIV with low CD4 undergoing chemotherapy or post-transplant would benefit Immunocompromised – no controlled studies but seems apparent that those with SCIDS or HIV with low CD4 undergoing chemotherapy or post-transplant would benefit Structural or functional lung disease (such as CF) are at increased risk; no data on effectiveness Structural or functional lung disease (such as CF) are at increased risk; no data on effectiveness

CONTINUITY CLINIC Medicaid and Synagis Synagis is a benefit under the Comprehensive Care Program Synagis is a benefit under the Comprehensive Care Program Administered by a Synagis provider Administered by a Synagis provider Eligibility for children under 2 the same except: Eligibility for children under 2 the same except: Hemodynamically significant heart disease is defined as including: Hemodynamically significant heart disease is defined as including: Pulmonary hypertension Pulmonary hypertension Digoxin or diuretics Digoxin or diuretics Oxygen Oxygen Lung disease qualifies if: Lung disease qualifies if: On steroids, diuretics, ventilator or 02 On steroids, diuretics, ventilator or 02 Transplants patients qualify Transplants patients qualify

CONTINUITY CLINIC RSV Vaccine Many challenges for effective vaccine Many challenges for effective vaccine Immature immunity Immature immunity Possible suppression of immune response by maternal antibody Possible suppression of immune response by maternal antibody Several antigenically divergent strains Several antigenically divergent strains Live attenuated vaccines are being tested Live attenuated vaccines are being tested Must be very attenuated in this young group Must be very attenuated in this young group However, lessens chance of detectable Ab response However, lessens chance of detectable Ab response

CONTINUITY CLINIC Post-test Which of the following children should receive RSV prophylaxis during RSV season? Which of the following children should receive RSV prophylaxis during RSV season? A. 5 month former 34 weeker who attends day care and has a 5 yo brother B. 11 month former 27 weeker C. 7 month former 31 weeker D. 18 month patient with cystic fibrosis on home 02 E. 14 month Tetrology of Fallot patient F. 22 month former 32 weeker with BPD who was required diuretics and steroids in October

CONTINUITY CLINIC Answer to Pretest Question There is evidence for lack of benefit in the 7 month old 31 weeker No evidence for benefit in cystic fibrosis patient but is reasonable to consider

CONTINUITY CLINIC References Up To Date, “Treatment and Prevention of RSV” Up To Date, “Treatment and Prevention of RSV” AAP Clinical Practice Guidelines, “Diagnosis and Management of Bronchiolitis”, PEDIATRICS Volume 118, Number 4, October 2006 AAP Clinical Practice Guidelines, “Diagnosis and Management of Bronchiolitis”, PEDIATRICS Volume 118, Number 4, October 2006 AAP Policy Statement, Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections AAP Policy Statement, Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections